ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-05-25 07:00 |
Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID…
|
English | HTML • 14.5 KB | ||
| 2020-05-22 00:00 |
URD 2020
|
French | PDF • 3.8 MB | ||
| 2020-05-20 18:05 |
Abivax postpones its Annual General Meeting to June 19, 2020
|
English | HTML • 8.8 KB | ||
| 2020-05-15 22:34 |
ABIVAX: 36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid…
|
English | HTML • 16.0 KB | ||
| 2020-05-14 06:00 |
ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human res…
|
English | HTML • 16.9 KB | ||
| 2020-04-29 19:53 |
Abivax postpones the publication of the yearly universal registration document …
|
English | HTML • 8.1 KB | ||
| 2020-03-16 19:32 |
Abivax 2019 Financial Results and Operations Update (news with additional featu…
|
English | HTML • 37.8 KB | ||
| 2020-03-11 18:00 |
Abivax 2020 Financial Communication Calendar
|
English | HTML • 7.2 KB | ||
| 2020-02-26 18:00 |
Abivax Includes First Patient in U.S. Phase 1/2 Clinical Trial of ABX196 to Tre…
|
English | HTML • 15.5 KB | ||
| 2020-02-26 18:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 240.9 KB | ||
| 2020-02-19 17:40 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 278.4 KB | ||
| 2020-01-28 18:09 |
Informations privilégiées / Autres communiqués
|
French | PDF • 164.2 KB | ||
| 2020-01-28 18:00 |
Abivax to Host Satellite Symposium at 15th Congress of the European Crohn's and…
|
English | HTML • 10.9 KB | ||
| 2020-01-23 18:00 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 278.5 KB | ||
| 2020-01-23 18:00 |
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | PDF • 220.2 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
